An oral presentation titled "Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results"
- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER. | May 25, 2023
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for .